Drug Approval | April 26, 2022
ZyCoV-D two-dose vaccine receives Emergency Use Approval from DCGI
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
Pre-exposure prevention trial reduced risk of symptomatic Covid-19, with no severe disease or Covid-19-related deaths in the Evusheld group
Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
The peptide-based vaccine induces a t cell-dependent response
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
Subscribe To Our Newsletter & Stay Updated
